TSXV:IOT

Stock Analysis Report

Executive Summary

Innovotech Inc. provides services and solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • Innovotech has significant price volatility in the past 3 months.
  • Innovotech is not covered by any analysts.

Share Price & News

How has Innovotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

70.0%

TSXV:IOT

3.7%

CA Life Sciences

1.4%

CA Market


1 Year Return

41.7%

TSXV:IOT

9.4%

CA Life Sciences

-4.1%

CA Market

IOT outperformed the Life Sciences industry which returned 9% over the past year.

IOT outperformed the Market in Canada which returned -4.9% over the past year.


Share holder returns

IOTIndustryMarket
7 Day70.0%3.7%1.4%
30 Day70.0%-3.4%-2.2%
90 Day41.7%2.7%-1.1%
1 Year41.7%41.7%9.6%9.4%-0.7%-4.1%
3 Year466.7%466.7%74.3%72.8%15.1%4.8%
5 Year112.5%112.5%111.0%101.0%12.8%-3.1%

Price Volatility Vs. Market

How volatile is Innovotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innovotech undervalued based on future cash flows and its price relative to the stock market?

40.69x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Innovotech to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Innovotech to establish if it is available at substantial discount.


Price Based on Earnings

Innovotech is loss making, we can't compare its value to the North America Life Sciences industry average.

Innovotech is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Innovotech, we can't assess if its growth is good value.


Price Based on Value of Assets

Innovotech is overvalued based on assets compared to the North America Life Sciences industry average.


Next Steps

Future Growth

How is Innovotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Innovotech performed over the past 5 years?

50.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Innovotech does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Innovotech's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Innovotech's 1-year growth to the North America Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Innovotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Innovotech has efficiently used its assets last year compared to the North America Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Innovotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Innovotech's financial position?


Financial Position Analysis

Innovotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Innovotech has no long term commitments.


Debt to Equity History and Analysis

Innovotech's level of debt (132.1%) compared to net worth is high (greater than 40%).

Innovotech had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Innovotech has less than a year of cash runway based on current free cash flow.

Innovotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 69.2% each year.


Next Steps

Dividend

What is Innovotech's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Innovotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Innovotech's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Innovotech has not reported any payouts.

Unable to verify if Innovotech's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Innovotech has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Innovotech's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average board tenure


CEO

James Timourian 0

0.0yrs

Tenure

CA$18,000

Compensation

Dr. James Timourian, Ph.D. has been the President of Innovotech Inc. since January 01, 2014 and serves as its Chief Executive Officer and Secretary. Dr. Timourian has been Mathematician President of Integr ...


CEO Compensation Analysis

James's remuneration is lower than average for companies of similar size in Canada.

Insufficient data for James to compare compensation growth.


Board Age and Tenure

4.1yrs

Average Tenure

The tenure for the Innovotech board of directors is about average.


Insider Trading

More shares have been bought than sold by Innovotech individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyCA$8,69931 Jul 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares128,000
Max PriceCA$0.07
BuyCA$10023 Jul 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares2,000
Max PriceCA$0.05
BuyCA$42021 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares7,000
Max PriceCA$0.06
BuyCA$35013 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$1,93011 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares30,000
Max PriceCA$0.07
BuyCA$12005 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares2,000
Max PriceCA$0.06
BuyCA$35004 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$3,71630 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares55,000
Max PriceCA$0.075
BuyCA$35028 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$6,32927 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares108,000
Max PriceCA$0.06
BuyCA$1,86924 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares30,000
Max PriceCA$0.065
BuyCA$3,82022 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares67,000
Max PriceCA$0.06
BuyCA$33001 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares6,000
Max PriceCA$0.055
BuyCA$72030 Apr 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares12,000
Max PriceCA$0.06
BuyCA$5,00015 Feb 19
David Tam
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceCA$0.05
BuyCA$42013 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares7,000
Max PriceCA$0.06
BuyCA$42008 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares6,000
Max PriceCA$0.07
BuyCA$1,05007 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares15,000
Max PriceCA$0.07
BuyCA$6006 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares1,000
Max PriceCA$0.06
BuyCA$5,00019 Jan 19
David Tam
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceCA$0.05
BuyCA$1,90018 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares38,000
Max PriceCA$0.05
BuyCA$5,00010 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$10,00009 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares200,000
Max PriceCA$0.05
BuyCA$15,00014 Dec 18
David Tam
EntityIndividual
Role
Member of the Board of Directors
Director
Shares300,000
Max PriceCA$0.05
BuyCA$6,25007 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares125,000
Max PriceCA$0.05
BuyCA$70006 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares14,000
Max PriceCA$0.05
BuyCA$25005 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.05
BuyCA$5,00004 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$5,50030 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$5,50021 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$5,50019 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$3,50018 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares70,000
Max PriceCA$0.05
BuyCA$5,00015 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$10,00014 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares200,000
Max PriceCA$0.05
BuyCA$1,15025 Sep 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares23,000
Max PriceCA$0.05
BuyCA$1,35020 Sep 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares27,000
Max PriceCA$0.05

Ownership Breakdown


Management Team

  • Alan Savage (76yo)

    CFO & Director

    • Tenure: 2.3yrs
  • James Timourian

    Chairman

    • Tenure: 0.0yrs
    • Compensation: CA$18.00k
  • Merle Olson

    Scientific Consultant

    • Tenure: 0.0yrs
  • Amin Omar

    Chief Operating Officer

    • Tenure: 0.0yrs
    • Compensation: CA$121.97k

Board Members

  • Gerard Tertzakian

    Independent Director

    • Tenure: 18.6yrs
  • Alan Savage (76yo)

    CFO & Director

    • Tenure: 2.3yrs
  • James Timourian

    Chairman

    • Tenure: 0.0yrs
    • Compensation: CA$18.00k
  • Bernard Grobbelaar

    Director

    • Tenure: 6.3yrs
    • Compensation: CA$37.50k
  • David Tam

    Director

    • Tenure: 1.0yrs
  • Craig Milne

    Director

    • Tenure: 0.1yrs

Company Information

Innovotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innovotech Inc.
  • Ticker: IOT
  • Exchange: TSXV
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.080m
  • Shares outstanding: 36.24m
  • Website: https://www.innovotech.ca

Number of Employees


Location

  • Innovotech Inc.
  • 2011-94 Street
  • Suite 101
  • Edmonton
  • Alberta
  • T6N 1H1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IOTTSXV (TSX Venture Exchange)YesClass A Common SharesCACADJul 2004

Biography

Innovotech Inc. provides services and solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada and internationally. The company’s products include InnovoSIL, the a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 23:46
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.